Abstract
Objective: To conduct a 16-week, randomized, placebo-controlled, double-blind trial of two GABAergic medications, baclofen (20 mg tid) and gabapentin (800 mg tid), for the treatment of methamphetamine dependence. Methods: Adults with methamphetamine dependence were randomized to one of three conditions for 16 weeks: baclofen (n = 25), gabapentin (n = 26) or placebo (n = 37). All participants attended clinic thrice weekly to receive study medication and psychosocial counseling, complete study assessments, and provide urine samples. Results: No statistically significant main effects for baclofen or gabapentin in reducing methamphetamine use were observed using a generalized estimating equation (GEE). A significant treatment effect was found in post hoc analyses for baclofen, but not gabapentin, relative to placebo among participants who reported taking a higher percentage of study medication (significant treatment group and medication adherence interaction in GEE model of methamphetamine use). Conclusions: While gabapentin does not appear to be effective in treating methamphetamine dependence, baclofen may have a small treatment effect relative to placebo. Future studies evaluating the effectiveness of baclofen and other GABAergic agents for treatment of methamphetamine may be warranted.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 177-184 |
| Number of pages | 8 |
| Journal | Drug and Alcohol Dependence |
| Volume | 85 |
| Issue number | 3 |
| DOIs | |
| State | Published - Dec 1 2006 |
Fingerprint
Keywords
- Baclofen
- Gabapentin
- Methamphetamine dependence
- Randomized clinical trial
ASJC Scopus subject areas
- Medicine(all)
- Behavioral Neuroscience
- Toxicology
- Health(social science)
Cite this
Randomized, placebo-controlled trial of baclofen and gabapentin for the treatment of methamphetamine dependence. / Heinzerling, Keith G.; Shoptaw, Steven; Peck, James A.; Yang, Xiaowei; Liu, Juanmei; Roll, John; Ling, Walter.
In: Drug and Alcohol Dependence, Vol. 85, No. 3, 01.12.2006, p. 177-184.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Randomized, placebo-controlled trial of baclofen and gabapentin for the treatment of methamphetamine dependence
AU - Heinzerling, Keith G.
AU - Shoptaw, Steven
AU - Peck, James A.
AU - Yang, Xiaowei
AU - Liu, Juanmei
AU - Roll, John
AU - Ling, Walter
PY - 2006/12/1
Y1 - 2006/12/1
N2 - Objective: To conduct a 16-week, randomized, placebo-controlled, double-blind trial of two GABAergic medications, baclofen (20 mg tid) and gabapentin (800 mg tid), for the treatment of methamphetamine dependence. Methods: Adults with methamphetamine dependence were randomized to one of three conditions for 16 weeks: baclofen (n = 25), gabapentin (n = 26) or placebo (n = 37). All participants attended clinic thrice weekly to receive study medication and psychosocial counseling, complete study assessments, and provide urine samples. Results: No statistically significant main effects for baclofen or gabapentin in reducing methamphetamine use were observed using a generalized estimating equation (GEE). A significant treatment effect was found in post hoc analyses for baclofen, but not gabapentin, relative to placebo among participants who reported taking a higher percentage of study medication (significant treatment group and medication adherence interaction in GEE model of methamphetamine use). Conclusions: While gabapentin does not appear to be effective in treating methamphetamine dependence, baclofen may have a small treatment effect relative to placebo. Future studies evaluating the effectiveness of baclofen and other GABAergic agents for treatment of methamphetamine may be warranted.
AB - Objective: To conduct a 16-week, randomized, placebo-controlled, double-blind trial of two GABAergic medications, baclofen (20 mg tid) and gabapentin (800 mg tid), for the treatment of methamphetamine dependence. Methods: Adults with methamphetamine dependence were randomized to one of three conditions for 16 weeks: baclofen (n = 25), gabapentin (n = 26) or placebo (n = 37). All participants attended clinic thrice weekly to receive study medication and psychosocial counseling, complete study assessments, and provide urine samples. Results: No statistically significant main effects for baclofen or gabapentin in reducing methamphetamine use were observed using a generalized estimating equation (GEE). A significant treatment effect was found in post hoc analyses for baclofen, but not gabapentin, relative to placebo among participants who reported taking a higher percentage of study medication (significant treatment group and medication adherence interaction in GEE model of methamphetamine use). Conclusions: While gabapentin does not appear to be effective in treating methamphetamine dependence, baclofen may have a small treatment effect relative to placebo. Future studies evaluating the effectiveness of baclofen and other GABAergic agents for treatment of methamphetamine may be warranted.
KW - Baclofen
KW - Gabapentin
KW - Methamphetamine dependence
KW - Randomized clinical trial
UR - http://www.scopus.com/inward/record.url?scp=33749498310&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33749498310&partnerID=8YFLogxK
U2 - 10.1016/j.drugalcdep.2006.03.019
DO - 10.1016/j.drugalcdep.2006.03.019
M3 - Article
C2 - 16740370
AN - SCOPUS:33749498310
VL - 85
SP - 177
EP - 184
JO - Drug and Alcohol Dependence
JF - Drug and Alcohol Dependence
SN - 0376-8716
IS - 3
ER -